IGF-1 LR3 Side Effects: What Studies Report

What IGF-1 LR3 Is in the Published Literature

IGF-1 LR3, also written Long R3 IGF-I or LongR³-IGF-I, is a structurally modified analogue of insulin-like growth factor 1 that appears in the scientific record mainly as a research reagent and as an analytical target. It is produced recombinantly rather than extracted from tissue: one 2023 paper described recombinant expression of both IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris as a production strategy (PMID 37261455). That production context matters for any discussion of adverse effects, because expression systems, fusion partners and purification tags are part of what ends up in a finished preparation.

The analogue's defining pharmacological feature in the literature is altered interaction with IGF binding proteins, which changes how the molecule distributes. A rat study published in 2000 compared the transport of circulating IGF-I and LR3IGF-I from blood to extracellular wound fluid sites, measuring how each form moved out of the circulation into tissue fluid compartments (PMID 10607940). Related in-vitro work on rabbit costal chondrocytes reported that IGF-I and dexamethasone differentially regulated IGF binding proteins in those cells (PMID 10828839), which is one reason researchers treat binding-protein status as a variable rather than a constant when interpreting growth-factor experiments.

Human Safety Data: What Studies Report

Stated plainly: among the verified sources reviewed for this page, there are no human clinical trials of IGF-1 LR3 reporting adverse events, tolerability, laboratory changes or dose-limiting toxicity. There is no published human dose-ranging study to summarise, no controlled human trial, and therefore no established incidence figures for any side effect. An absence of reported adverse events in the literature is not the same as evidence of safety; it means the studies that would generate such data have not been published in the sources available here.

What does exist in the human-facing literature is analytical chemistry. Researchers developed an immunopurification and high-resolution mass spectrometry method to detect LongR³-IGF-I, Des(1-3)-IGF-I and R³-IGF-I for anti-doping purposes (PMID 33587816), and a separate 2024 paper described chromatographic–mass spectrometric analysis of peptidic analytes in the 2–10 kDa range in doping control urine samples (PMID 38197510). Those papers document that the analogue is treated as a detectable substance in sport testing; they do not report clinical outcomes or adverse effects.

Animal Studies: What Studies Report

Most of the in-vivo signal relevant to IGF-1 analogues comes from fetal sheep work using native IGF-1 infusions. That distinction should be held in mind throughout: these were IGF-1 studies in a developmental model, not LR3 studies in adults, and the findings cannot be transferred directly.

Glucose handling and pancreatic islet function

The most concrete adverse-direction finding in the verified set concerns insulin secretion. A 2021 study reported that reduced glucose-stimulated insulin secretion following a one-week IGF-1 infusion in late-gestation fetal sheep was due to an intrinsic islet defect rather than to changes in the surrounding metabolic environment (PMID 33938236). The study located the change at the level of the islet itself, which is a mechanistic observation about how sustained growth-factor exposure can alter an endocrine tissue's own behaviour. Because IGF-1 and insulin receptors share structural similarity, glucose-related effects are the class of observation that researchers most often examine in this family of molecules.

Organ growth that is not proportional

Two related sheep studies reported growth effects that were not uniform across the body. Researchers reported that sheep recombinant IGF-1 promoted organ-specific growth in fetal sheep (PMID 36091374), and a companion 2021 paper reported that IGF-1 infusion to fetal sheep increased organ growth but did not do so by stimulating nutrient transfer to the fetus (PMID 33427051). The second finding is the more interesting one for a side-effect discussion: the growth response occurred without the expected increase in nutrient supply, meaning the tissue changes were driven by direct signalling rather than by improved nutrition. Organ-selective growth is, in a toxicology frame, a finding to be characterised rather than assumed benign.

Distribution beyond the bloodstream

The rat transport study is relevant to how far an IGF analogue reaches. That work examined movement of circulating IGF-I and LR3IGF-I from blood to extracellular wound fluid sites (PMID 10607940), a compartment-to-compartment question. Any molecule that reaches more tissue compartments has more opportunity to act on tissues that were not the intended target — which is a general pharmacological principle, not a reported adverse event.

Cell Studies: What Studies Report

Cardiac cells

A 2003 study reported that extracellular signal-regulated kinase and phosphoinositol-3 kinase mediated IGF-1-induced proliferation of fetal sheep cardiomyocytes (PMID 12947030). The study was mechanistic, identifying which intracellular pathways carried the proliferative signal in heart muscle cells. It did not assess cardiac structure or function in a living adult animal, and it did not test the LR3 analogue.

Ovarian follicles

In a bovine model, researchers examined the effects of IGF-I bioavailability on preantral follicular development in vitro (PMID 17636166). Bioavailability — how much free growth factor is available to receptors once binding proteins are accounted for — is precisely the variable that analogues with altered binding-protein affinity change, which is why reproductive-tissue culture work appears in this literature at all.

Cartilage cells and binding proteins

The rabbit chondrocyte study reported differential regulation of IGF binding proteins by IGF-I and dexamethasone (PMID 10828839), illustrating that binding-protein expression in a given tissue is itself responsive to hormonal input rather than fixed.

Muscle-wasting research for context

Adjacent work on muscle preservation has often targeted other pathways entirely. A 2019 study reported that inhibition of activin-like kinase 4/5 attenuated cancer cachexia-associated muscle wasting (PMID 31285507). It is cited here only to show where controlled preclinical muscle-wasting research has actually been conducted; it did not evaluate IGF-1 LR3.

Product Identity and Purity: What Studies Report

One published finding sits outside pharmacology and inside product quality. A 2010 analysis reported the detection of His-tagged Long-R³-IGF-I in a black market product (PMID 20675162). A histidine tag is a purification handle left over from recombinant manufacturing; its presence in a distributed product indicates a preparation that was not processed to a pharmaceutical standard. Combined with the recombinant expression work describing fusion-partner strategies in yeast (PMID 37261455), this points to a practical limitation of the whole topic: material circulating outside of regulated supply chains may differ in identity and purity from the material used in laboratories, which makes any inference about effects from unregulated products unreliable.

Summary of the Verified Evidence

Why the Literature Is Thin

IGF-1 LR3 was developed as a cell-culture supplement and research reagent, not as a therapeutic candidate, so the usual pipeline that generates safety data — toxicology packages, phase I tolerability studies, post-marketing surveillance — was never run for it. The papers that mention it by name in the verified set are a production paper (PMID 37261455), a rat distribution paper (PMID 10607940), a black-market product analysis (PMID 20675162) and two analytical detection papers (PMID 33587816, PMID 38197510). Everything else summarised above studied native IGF-1 in animals or cells.

What the Literature Does Not Establish

• No human adverse-event frequencies, severity gradings or tolerability data appear in the verified sources.
• No human dosing information is reported, so no dose-related risk relationship can be described.
• Long-term outcomes, including any oncological or cardiovascular endpoints, were not assessed in the studies cited here.
• Effects observed with native IGF-1 in fetal sheep or in cultured cells were not shown to transfer to the LR3 analogue in adult humans.
• Purity, sterility and identity of material outside controlled research settings were not verified, and one analysis found residual manufacturing tags in a market product (PMID 20675162).

How to Read a Thin Evidence Base

Reporting an absence honestly is more useful than filling it with extrapolation. The reasonable summary of this literature is: mechanistic and animal work shows that IGF-1 signalling changes glucose-stimulated insulin secretion in at least one developmental model (PMID 33938236) and drives tissue-selective growth and cell proliferation (PMID 36091374, PMID 12947030); whether, at what exposure, and with what consequences any of that occurs in humans given IGF-1 LR3 has not been reported. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, laboratory finding or substance discussed here.

References

• Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris (Applied Microbiology and Biotechnology, 2023)
• Sheep recombinant IGF-1 promotes organ-specific growth in fetal sheep (Frontiers in Physiology, 2022)
• IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus (American Journal of Physiology: Endocrinology and Metabolism, 2021)
• Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect (American Journal of Physiology: Endocrinology and Metabolism, 2021)
• Transport of circulating IGF-I and LR3IGF-I from blood to extracellular wound fluid sites in rats (The Journal of Endocrinology, 2000)
• Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1 induced proliferation of fetal sheep cardiomyocytes (American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 2003)
• Effects of IGF-I bioavailability on bovine preantral follicular development in vitro (Reproduction, 2007)
• Differential regulation of IGF-binding proteins in rabbit costal chondrocytes by IGF-I and dexamethasone (The Journal of Endocrinology, 2000)
• Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting (Scientific Reports, 2019)
• Detection of His-tagged Long-R³-IGF-I in a black market product (Growth Hormone & IGF Research, 2010)
• Detection of LongR³-IGF-I, Des(1-3)-IGF-I, and R³-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes (Drug Testing and Analysis, 2021)
• Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples (Journal of Mass Spectrometry, 2024)